


(Global)

CO-338-087/GOG-3020/ENGOT-ov45 (Joint International Steering Committee)



Primary Endpoint

- PFS by Investigator in molecularly-defined HRD subgroups

Secondary Endpoints

- PFS by BICR in molecularly-defined HRD subgroups
- ORR and DOR in patients with measurable disease
- OS and Safety

Status: Ongoing Accrual

Target: 1000 pts

Notes: